249 related articles for article (PubMed ID: 15045037)
1. New additions to the intensive care armamentarium.
Rice TW; Bernard GR
Drugs Today (Barc); 2004 Feb; 40(2):157-70. PubMed ID: 15045037
[TBL] [Abstract][Full Text] [Related]
2. The current management of septic shock.
Russel JA
Minerva Med; 2008 Oct; 99(5):431-58. PubMed ID: 18971911
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of recombinant human activated protein C for severe sepsis.
Bernard GR; Vincent JL; Laterre PF; LaRosa SP; Dhainaut JF; Lopez-Rodriguez A; Steingrub JS; Garber GE; Helterbrand JD; Ely EW; Fisher CJ;
N Engl J Med; 2001 Mar; 344(10):699-709. PubMed ID: 11236773
[TBL] [Abstract][Full Text] [Related]
4. Erythropoietic agents for anemia of critical illness.
Shermock KM; Horn E; Rice TL
Am J Health Syst Pharm; 2008 Mar; 65(6):540-6. PubMed ID: 18319499
[TBL] [Abstract][Full Text] [Related]
5. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).
Micek ST; Isakow W; Shannon W; Kollef MH
Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217
[TBL] [Abstract][Full Text] [Related]
6. Blood conservation in the critically ill.
Thomas J; Martinez A
Am J Health Syst Pharm; 2007 Aug; 64(16 Suppl 11):S11-8. PubMed ID: 17687066
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of epoetin alfa in critically ill patients.
Corwin HL; Gettinger A; Fabian TC; May A; Pearl RG; Heard S; An R; Bowers PJ; Burton P; Klausner MA; Corwin MJ;
N Engl J Med; 2007 Sep; 357(10):965-76. PubMed ID: 17804841
[TBL] [Abstract][Full Text] [Related]
8. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.
Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR;
Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987
[TBL] [Abstract][Full Text] [Related]
9. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
Rice TW
Vasc Health Risk Manag; 2006; 2(1):3-18. PubMed ID: 17319465
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
11. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis.
De Backer D
Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539
[TBL] [Abstract][Full Text] [Related]
12. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis.
Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ;
Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943
[TBL] [Abstract][Full Text] [Related]
13. Extended drotrecogin alfa (activated) treatment in patients with prolonged septic shock.
Dhainaut JF; Antonelli M; Wright P; Desachy A; Reignier J; Lavoue S; Charpentier J; Belger M; Cobas-Meyer M; Maier C; Mignini MA; Janes J
Intensive Care Med; 2009 Jul; 35(7):1187-95. PubMed ID: 19263034
[TBL] [Abstract][Full Text] [Related]
14. Drotrecogin alfa (activated) for the treatment of severe sepsis and septic shock.
Rice TW; Bernard GR
Am J Med Sci; 2004 Oct; 328(4):205-14. PubMed ID: 15486535
[TBL] [Abstract][Full Text] [Related]
15. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
16. Is there a place for epoetin alfa in managing anemia during critical illness?
Givens M; Lapointe M
Clin Ther; 2004 Jun; 26(6):819-29. PubMed ID: 15262453
[TBL] [Abstract][Full Text] [Related]
17. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis.
McCoy C; Matthews SJ
Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504
[TBL] [Abstract][Full Text] [Related]
18. Anemia in the critically ill.
Shander A
Crit Care Clin; 2004 Apr; 20(2):159-78. PubMed ID: 15135458
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial.
Corwin HL; Gettinger A; Pearl RG; Fink MP; Levy MM; Shapiro MJ; Corwin MJ; Colton T;
JAMA; 2002 Dec; 288(22):2827-35. PubMed ID: 12472324
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: results of a randomized, double-blind, placebo-controlled trial.
Vincent JL; Spapen HD; Creteur J; Piagnerelli M; Hubloue I; Diltoer M; Roman A; Stevens E; Vercammen E; Beaver JS
Crit Care Med; 2006 Jun; 34(6):1661-7. PubMed ID: 16607233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
